Orchid Pharma Limited β Q2FY27 earnings call summary
Filed 20 November 2026 Β· Official transcript
- No short-term margin guidance; focus on cost control and product mix
- Cefiderocol project commissioning targeted Dec 2026; India launch Q3 FY27
- Merger benefits expected to show cost savings by end FY27
- Q2 FY27 revenue grew 14% y-y to INR341 Cr; H1 revenue up 15% to INR645 Cr
- Working capital improved; operating cash flow INR118 Cr in H1 FY27
- 7-ACA plant commissioning planned Mar 2027; capacity 1,000 MT/year
- Gross margin improved ~8 ppts to 39% in Q2; H1 margin at 36%
- Q2 EBITDA rose 148% to INR52 Cr; EBITDA margin 15% vs 7% last year
Open source transcript Β· View Orchid Pharma Limited research
Sign in free to track Orchid Pharma Limited and receive future summaries.